ScandiBio Therapeutics AB Report issue

For profit Phase 3
Founded: Stockholm Sweden (2017)

Organization Overview

First Clinical Trial
2019
NCT04330326
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ScandiBio Therapeutics AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Fatty Liver (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5